Zacks Investment Research | Jan 02, 2020 09:55PM ET
Pulmatrix, Inc. (NASDAQ:PULM) announced that it has inked a licensing and development agreement with the Lung Cancer Initiative at Johnson & Johnson (NYSE:JNJ) . The agreement grants the Lung Cancer Initiative an option to gain rights to Pulmatrix’s portfolio of narrow spectrum kinase inhibitors, including an early-stage candidate PUR1800. These candidates are intended to be developed for lung cancer interception.
Per the terms of the agreement, Pulmatrix will receive $7.2 million in upfront payment and is eligible to receive additional $2 million in milestone payments on completion of an early-stage clinical study on PUR1800. The study is expected to be completed by 2020-end. Moreover, if the Lung Cancer Initiative exercises its option to gain rights to the portfolio of narrow spectrum kinase inhibitors, Pulmatrix will be eligible to receive $91 million in development and commercial milestones. The company will also be eligible to receive royalty payments.
Shares of Pulmatrix surged 88.4%, following the deal announcement. This is because the deal is expected to boost its cash resources, which will likely support future clinical activities. On its third-quarter earnings call, the company had stated that it lacks sufficient funds to support clinical activities for any of its pipeline candidates beyond third-quarter 2020. Shares of the company have declined 50.7% in the past year against the industry ’s increase of 3.8%.
Pulmatrix is a clinical stage biopharmaceutical company, which is focused on developing inhaled therapies for treating serious pulmonary disease using its patented iSPERSE technology.
We note that the company had in-licensed a portfolio of novel drug candidates consisting of kinase inhibitors from a wholly owned subsidiary of J&J in 2017. The company stated in its press release that it has unlocked clinical potential of PUR1800 using its iSPERSE technology. The candidate is intended to be developed for treating acute exacerbations in patients with COPD and is currently being evaluated in a phase Ib study.
Apart from PUR1800, the company has other pipeline candidates using iSPERSE technology in clinical development, which includes Pulmazole. An inhaled formulation of the anti-fungal drug itraconazole, Pulmazole is the most advanced candidate, which is being developed in a phase II study for treating allergic bronchopulmonary aspergillosis in patients with asthma.
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.